Physician profile
Stephen Zerby
NPI 1679549653
$1,128.90
in general payments reported to CMS, 2019-2025
16 companies · $54.79 in 2025
The $54.79 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $632 · 2020: $146 · 2021: $17.82 · 2022: $243 · 2023: $19.07 · 2024: $15.60 · 2025: $54.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $89.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $89.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $361.67 | 2019-2022 | |
| Allergan, INC. | $165.86 | 2019-2020 | |
| Lundbeck LLC | $163.02 | 2019-2020 | |
| Alkermes, INC. | $72.90 | 2019-2025 | Aristada, Lybalvi |
| Indivior INC. | $60.19 | 2019 | |
| Ironshore Pharmaceuticals INC. | $57.01 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $55.52 | 2019-2024 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $37.26 | 2025 | |
| Corium, LLC | $34.32 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.60 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.07 | 2023 | Austedo Xr |
| Abbvie INC. | $17.82 | 2021 | |
| Vertical Pharmaceuticals, LLC | $17.04 | 2019 | |
| Shire North American Group INC | $14.92 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.31 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Zerby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.